HPV Testing and Cervical Screening in the UK

Slides:



Advertisements
Similar presentations
HPV 101.
Advertisements

Introducing HPV triage and test of cure into the NHS Cervical Screening Programme SEC Cancer Screening QA Reference Centre & Maggie Cooper, Maggie Cooper.
RESULTS: After Discordant Analysis RESULTS: Discordant Testing
Analytical Performance of the APTIMA HPV Assay on the PANTHER Analyzer
Clinical Performance of the APTIMA HPV Assay for Detection of E6/E7 mRNA from High-Risk HPV Types in Liquid Based Cytology Specimens C. Hill1, J. Dockter1,
Nick Curry, MD, MPH Infectious Diseases Prevention Section
For primary and secondary care settings
NHS CERVICAL SCREENING PROGRAMME AND REFERRAL PATTERNS FOR COLPOSCOPY Dr Sue Calvert.
New Developments In the Cervical Screening Programme
HPV Testing and Genotyping
Molecular testing for detection of Mycobacterium tuberculosis San Francisco Department of Public Health Laboratory.
` COMPARATIVE ACCURACY OF CARTRIDGE BASED NUCLEIC ACID AMPLIFICATION TEST AND SPUTUM MICROSCOPY FOR DIAGNOSIS OF PULMONARY TUBERCULOSIS IN HIV POSITIVE.
Group 3 – Michael, Elani, Golshan, Sarah, Joseph, Nana
Mark Jit Modelling and Economics Unit Health Protection Agency, London Case study: Structural uncertainty in human papillomavirus vaccination modelling.
Sexually Transmitted Disease Surveillance 2012 Division of STD Prevention.
Before Between After.
2011 FRANKLIN COMMUNITY SURVEY YOUTH RISK BEHAVIOR GRADES 9-12 STUDENTS=332.
CANCER SCREENING 2011 DELAWARE CANCER EDUCATION ALLIANCE STEPHEN S. GRUBBS, M.D. HELEN F. GRAHAM CANCER CENTER DELAWARE CANCER CONSORTIUM OCTOBER 5, 2011.
How do we delay disease progress once it has started?
1 Cervical Screening Programme, England, : Graphs.
HPV-vaccines – a breakthrough in medicine Björn Strander Onkologiskt centrum Västra regionen and Kungsbacka Närsjukhus Sweden.
HPV-RELATED CANCER Understanding the Burden of HPV Disease and the Importance of the HPV Vaccine Recommendation Lois Ramondetta, MD Professor Gynecologic.
HPV.  Many risk factors for development of cervical cancer. no routinely used positive predictive biological markers, which identify women at risk of.
Cervical Screening and HPV testing
HPV Sample Taker Training South West Regional Cytology Training Centre Southmead Hospital Bristol.
Spotlight on Cervical Cancer Screening
Ai Ling Tan Gynaecological Oncologist Ascot Clinic/ADHB NCSP UPDATE & PRIMARY HPV SCREENING.
Anticipated impact on HPV infection from HPV vaccination programs – cause for optimism Dr Paddy Horner.
Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening Obstetrics and Gynecology, Volume 103,
Clinical Uses of HPV DNA Testing
Human Papilloma virus testing Research Center for Genetic Engineering and Biotechnology “Georgi D. Efremov”, MASA What is Human Papillomavirus? Human papilloma.
COLPOSCOPY Cervical Screening QARC Training School October 2012.
November 2005 Guy Hayhurst Consultant in Public Health, Eastern Cheshire PCT OVERVIEW OF THE CERVICAL SCREENING PROGRAMME.
04/05/20041 Liquid Based Cytology Workshop. 04/05/20042 Programme content Session 1 : Overview of the cervical screening programme & why LBC has been.
Educational Module Cervical Cancer Screening.  Estimated new cases: 610  Estimated deaths: 150 Regular Pap tests combined with the HPV vaccine can.
HPV Vaccination - the end of the road for cervical cancer? Alison Fiander Wales College of Medicine Cardiff University.
The Role of the Cytology Laboratory
Review of the Guidelines for Cervical Screening in New Zealand Presentation for smear-takers September 2008.
CANCER CERVIX A PREVENTABLE CANCER Dr NEETA DHABHAI Sr Consultant. – Gynaecologist Member Expert - Indian Cancer Winners’ Association
Cervical Sample Taker Training 2015 THE NHS CERVICAL SCREENING PROGRAMME (NHSCSP)
Overview of NHS Cervical Screening Programme Cervical Screening QARC Training School October 2012.
SoftPAP® A Novel Collection Device for Cervical Cytology.
GYNAEPATH.
Screening for cervical cancer. Screening for cervical lesions Common disease Cancer is preventable Screening is easy MUST BE PERFORMED.
NHS Cervical Screening Programme, England, : Graphs.
Hot Topics Clinical Medicine ACHA Annual Meeting Boston, MA May 31, 2013.
David Y. Zhang MD, PhD, MPH Professor Director, Molecular Pathology Departments of Pathology Icahn School of Medicine at Mount Sinai, New York Molecular.
1 Cervical Screening Programme, England, : Graphs.
Sheffield Gynaecological Cancer CentreSheffield Teaching Hospitals PRIMARY HPV SCREENING A view from colposcopy John Tidy Consultant Gynaecological Oncologist.
1 Cervical Screening Programme, England, : Graphs.
NHS Cervical Screening Programme, England, : Graphs.
HPV testing as a Primary screening tool in England Dr Karin Denton.
Appendix 2 Comparison of screening from age 20 and age 25 Table of harms and benefits.
NHS Cervical Screening Programme Introducing HPV triage and test of cure.
HPV and Pap Guidelines Jennifer Johnson MD. Objectives 1. Define the new PAP guidelines. 2. Identify the historical trends and new evidence resulting.
Results of the HTA Adequacy Study JHF Smith Royal Hallamshire Hospital, Sheffield BAC Scientific Meeting 2013.
New Technologies in cervical cancer screening Cosette Wheeler, University of New Mexico Albuquerque, New Mexico.
Public Health England leads the NHS Screening Programmes
Cancer prevention and early detection
Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions ELINA VIRTANEN1, ILKKA KALLIALA2,3,
NHS Cervical Screening Programme Introducing HPV Triage
Cervical Screening Programme, England, : Graphs
2nd WORLD GYNECOLOGIC CANCER CONFERENCE
Retest in 12mo with HPV testing
NHS Cervical Screening Programme, England : Graphs
Dr Sam Hibbitts HPV Research Team Obstetrics & Gynaecology
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Public Health England leads the NHS Screening Programmes
Fig. 2. Three cervical screening strategies to detect CIN2+/CIN3+
Presentation transcript:

HPV Testing and Cervical Screening in the UK Alex Sargent HPA Manchester

Human Papillomaviruses Mainly infect the anogenital tract ( approx 40 genotypes) Quite often asymptomatic LOW RISK (20 Types including types 6 and 11) Anogenital warts Very rarely found in cancers HIGH RISK (approx 14 types) Precursor lesions (CIN) cervical cancer Most malignancies of the anogenital tract

99.7% of cervical cancers are directly linked to previous infection with a High Risk HPV type Walboomers et al 1999

High-risk HPV Prevalence (N=24,510) Percentage of HR HPV Age Group Kitchener et al 2006

HR HPV Type by Cytology Grade % of Type Specific HPV Prevalence Cytology Grade

MRI Involvement in HPV Malignant progression of laryngeal papilloma associated with human papilloma virus type 6 (HPV-6) DNA. A P Zarod, J D Rutherford, and G Corbitt. J Clin Pathol. 1988; 41: 280–283 Anal human papillomavirus and anal cancer. Tilston P. J Clin Pathol. 1997; 50:625-34 A study of anal intraepithelial neoplasia in HIV positive homosexual men. Lacey HB, Wilson GE, Tilston P, Wilkins EG, Bailey AS, Corbitt G, Green PM. Sex Transm Infect. 1999; 75:172-7 Natural history of cervical human papillomavirus infection in women during their first sexual relationship. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS. Lancet. 2001; 357:1831-6

More recent work has been our involvement in the ARTISTIC Trial Designed to investigate the value of incorporating HPV testing in to the English cervical cancer screening programme • Kitchener at al. Br J Cancer 2006; 95(1): 56-61 • Sargent et al. Br J Cancer 2008; 98(10):1704-9 • Kitchener et al Lancet Oncol. 2009;10(8):748. • Kitchener at al Health Technol Assess. 2009; 13(51):1-150, iii-iv • Sargent et al. J Clin Microbiol. 2010; 48(2), 554-8 • Kitchener at al Eur J Cancer. 2011; 47(6):864-71

ARTISTIC Trial Main findings • Primary cervical screening with combined LBC and HPV testing resulted in only a small reduction in the detection of high grade disease at the next screening round compared to LBC alone • HPV testing, either for triage or as the initial screening test triaged by cytology, would be cost effective with no loss of sensitivity • The screening interval could be increased from 3 to at least 6 years • No significant adverse psychosocial effects were detected

NHS HPV Triage Pilot Studies Studies showed A reduction of inadequate smears (from 9% conventional cytology to 1-2% LBC) • 46% (1680/3681) BNC & 83% (1507/1825) mild dyskaryosis were HPV positive • The rate of repeat smears fell by 74% (70% for BNC & 87% for mild) • Rate of referral to colposcopy more than doubled (increased from 15%-44% for BNC & 37% - 80% for mild) • Direct referral of HPV positive women to colposcopy may lead to increased detection of CIN2+ Legood. BMJ 2006; 332:79-83 Moss. BMJ 2006; 332:83-85

Sentinel Sites project Funded by the NHS Cervical Screening Programme HPV Triage March 2008 -2011, 6 cytology centres (approx. 10% screening population in England) acted as sentinel sites for HPV triage In the event of borderline or mild dyskaryosis cytology, residual material is tested for HR HPV using the Hybrid Capture 2 test (≥2RLU/Co) HPV Positive women are referred to colposcopy HPV Negative women are returned to routine recall (HPV testing has a high NPV) Virology testing centralised in Manchester Virology lab and Bristol Cytology lab

Sentinel Sites project Test of cure In the event of an abnormal cytology report post-treatment, women are referred for colposcopy (standard practice) In the event of a normal cytology report, residual material is tested for high risk HPV by HC2 (≥2 RLU/Co) HPV negative women are referred for 3-year recall ( rather than annual recall for 10 years) and HPV positive women referred for colposcopy HPV-directed referral strategy is of considerable benefit to women in terms of reducing anxiety, uncertainty and the need for repeat smears, as well as reducing work load in cytology Kitchener et al. BJOG 2008; 115:1001-1007

HR HPV Positivity Rate by Referral Site

Improvements to the NHS CSP Increased identification of high grade CIN and increased specificity in women undergoing HPV triage HPV triage offers immediate referral to colposcopy for those who may have significant disease & rapid return to routine recall for women unlikely to have significant disease due to high NPV of HPV testing HPV ToC offers rapid return to routine recall for treated women (approx. 80%) Reduced repeat testing will give rise to savings in primary care and laboratories

HPV TESTING NEW TECHNOLOGIES STUDY .

Qiagen HC2 assay Clinically regarded as the “Gold Standard” Approved cervical specimens include Cytyc ThinPrep PreservCyt® solution & SurePath preservative fluid Signal amplification DNA screening assay Targets 13 HR types Semi-automated system available No internal control for sample integrity Known issues regarding cross-reactivity

Qiagen Hybrid Capture 2 (HC2) Test

The Rapid Capture™ System Courtesy of Digene

ALTERNATIVE HPV TESTS

Basic Methodologies HPV Detection performed by molecular assays - Signal Amplification (HC2 ; Cervista) - Nucleic Acid Amplification (PCR ; TMA ; NASBA)

Screening assays Genotyping assays Designed to detect the group of High Risk HPV Genotypes Some assays also have limited genotyping capacity for types 16 and 18 Genotyping assays Designed to Genotype the majority of the HPV types infecting the Genital Tract-particularly the High Risk Genotypes Usually based on either a line blot assay format or micro-array system As yet of questionable value in the cervical screening programme

Some Commercial Screening Assays Qiagen HC2 GenProbe APTIMA Roche AMPLICOR Roche Real Time Abbott Real Time Hologic Cervista Norchip Bio-Tools Gen ID Genomica

Clinical Validation • In the case of HPV infections there is a big difference between analytical sensitivity and clinical sensitivity /specificity • Meijer CJ et al have recently developed guidelines for high-risk HPV test requirements for primary cervical screening and validation guidelines for candidate HPV assays Int J Cancer 2009 Feb 1 124 (3) 516-20

Guidelines for HPV Testing The sensitivity of the candidate test for CIN2+ should be at least 90%** of the sensitivity of the HC2 assay to Detect Clinical Disease The specificity of the candidate test for CIN2+ should be at least 98% of the specificity of the HC2 assay **For our study the minimum sensitivity has been raised to 95%

New Technologies Study Aim • To demonstrate non-inferiority of any new test relative to Qiagen Hybrid Capture 2, in terms of both sensitivity and specificity for detection of high grade disease (≥CIN2) • To assess the clinical utility of the test for triage of low grade cytology • New tests were assessed at Bristol HPA and Manchester HPA - 2500 SurePath LBC and 2500 ThinPrep LBC

Commercial Assays Under Evaluation New Test Surepath Thinprep Roche Cobas 4800  Abbott rt HPV Gen-probe HPV APTIMA ++ Hologic Cervista HPV ++ non-CE marked

Conclusions All assays so far have proved non-inferior to the HC2 assay Genprobe (SurePath) and Hologic are still under evaluation New tests are highly automated All assays have internal controls Abbott and Roche tests can simultaneously detect and identify types 16 and 18

Possible Future Setting up of sentinel sites to pilot primary HPV testing in cervical screening Use of self sampling to improve coverage of the cervical screening programme

Acknowledgements Prof Henry Kitchener and the ARTISTIC Team Prof Julietta Patnick and members of the NHSCSP Members of the Primary Screening Group Andrew Bailey and Staff in Virology, Manchester Royal Infirmary